MX368017B - Compuestos de indazol como agonistas del receptor de 5-ht4. - Google Patents
Compuestos de indazol como agonistas del receptor de 5-ht4.Info
- Publication number
- MX368017B MX368017B MX2016007857A MX2016007857A MX368017B MX 368017 B MX368017 B MX 368017B MX 2016007857 A MX2016007857 A MX 2016007857A MX 2016007857 A MX2016007857 A MX 2016007857A MX 368017 B MX368017 B MX 368017B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- receptor agonists
- indazole compounds
- formula
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con compuestos de indazol novedosos de la fórmula (I), incluyendo sus estereoisómeros y sus sales farmacéuticamente aceptables. La presente invención también se relaciona con métodos de elaboración de tales compuestos y de composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos de la presente invención son útiles en el tratamiento de varios trastornos que se relacionan con agonistas de receptores de 5-hidroxitriptamina 4 (5-HT4). (Ver fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN5852CH2013 | 2013-12-16 | ||
PCT/IN2014/000116 WO2015092804A1 (en) | 2013-12-16 | 2014-02-24 | Indazole compounds as 5-ht4 receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016007857A MX2016007857A (es) | 2016-09-07 |
MX368017B true MX368017B (es) | 2019-09-13 |
Family
ID=50736125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016007857A MX368017B (es) | 2013-12-16 | 2014-02-24 | Compuestos de indazol como agonistas del receptor de 5-ht4. |
Country Status (17)
Country | Link |
---|---|
US (1) | US9951045B2 (es) |
EP (1) | EP3099675B1 (es) |
JP (1) | JP6161823B2 (es) |
KR (1) | KR101824154B1 (es) |
CN (1) | CN105873920B (es) |
AP (1) | AP2016009253A0 (es) |
AU (1) | AU2014369085B2 (es) |
BR (1) | BR112016013974B1 (es) |
CA (1) | CA2932428C (es) |
DK (1) | DK3099675T3 (es) |
EA (1) | EA029951B1 (es) |
ES (1) | ES2668873T3 (es) |
IL (1) | IL245948B (es) |
MX (1) | MX368017B (es) |
NZ (1) | NZ720879A (es) |
SG (1) | SG11201604849YA (es) |
WO (1) | WO2015092804A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3180333T3 (pl) | 2014-08-16 | 2020-12-28 | Suven Life Sciences Limited | Proces przygotowania na dużą skalę szczawianu 1-izopropylo-3-{5- [1-(3-metoksypropylo) piperydyn-4-ylo]-[1,3,4]oksadiazol-2-ilo}-1h-indazolu |
TR201909997T4 (tr) * | 2015-02-13 | 2019-07-22 | Suven Life Sciences Ltd | 5-HT4 reseptör agonistleri olarak amid bileşikleri. |
EP4317141A1 (en) | 2022-08-04 | 2024-02-07 | Curia Spain S.A.U. | Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5150393A (en) | 1992-10-13 | 1994-05-09 | Smithkline Beecham Plc | Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists |
AU680453B2 (en) | 1992-11-05 | 1997-07-31 | Smithkline Beecham Plc | Piperidine derivatives as 5-HT4 receptor antagonists |
CA2461159A1 (en) | 2001-10-22 | 2003-05-01 | Pfizer Inc. | Imidazopyridine compounds as 5-ht4 receptor modulators |
BRPI0409592A (pt) | 2003-04-21 | 2006-05-02 | Pfizer | compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3 |
ES2338882T3 (es) | 2003-11-24 | 2010-05-13 | Pfizer, Inc. | Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4. |
EP1701951B1 (en) * | 2003-12-23 | 2010-02-10 | Serodus AS | Modulators of peripheral 5-ht receptors |
CA2588037A1 (en) * | 2004-12-22 | 2006-06-29 | Theravance, Inc. | Indazole-carboxamide compounds |
DK1856114T3 (en) | 2005-02-25 | 2014-11-17 | Raqualia Pharma Inc | Benzisoxazol-DERIVATIVES |
US7906532B2 (en) | 2005-07-22 | 2011-03-15 | Pfizer Inc. | Indazole derivatives |
RU2569733C2 (ru) * | 2010-02-12 | 2015-11-27 | Раквалиа Фарма Инк. | Агонисты 5-нт4-рецепторов для лечения деменции |
CN102762554A (zh) | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
BR112014001083B8 (pt) * | 2011-09-19 | 2022-06-14 | Suven Life Sciences Ltd | Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto |
-
2014
- 2014-02-24 JP JP2016539987A patent/JP6161823B2/ja active Active
- 2014-02-24 WO PCT/IN2014/000116 patent/WO2015092804A1/en active Application Filing
- 2014-02-24 MX MX2016007857A patent/MX368017B/es active IP Right Grant
- 2014-02-24 KR KR1020167015974A patent/KR101824154B1/ko active IP Right Grant
- 2014-02-24 US US15/104,521 patent/US9951045B2/en active Active
- 2014-02-24 CA CA2932428A patent/CA2932428C/en active Active
- 2014-02-24 ES ES14725246.4T patent/ES2668873T3/es active Active
- 2014-02-24 DK DK14725246.4T patent/DK3099675T3/en active
- 2014-02-24 BR BR112016013974-7A patent/BR112016013974B1/pt active IP Right Grant
- 2014-02-24 EA EA201691252A patent/EA029951B1/ru unknown
- 2014-02-24 EP EP14725246.4A patent/EP3099675B1/en active Active
- 2014-02-24 AP AP2016009253A patent/AP2016009253A0/en unknown
- 2014-02-24 NZ NZ720879A patent/NZ720879A/en not_active IP Right Cessation
- 2014-02-24 CN CN201480068132.6A patent/CN105873920B/zh active Active
- 2014-02-24 AU AU2014369085A patent/AU2014369085B2/en not_active Ceased
- 2014-02-24 SG SG11201604849YA patent/SG11201604849YA/en unknown
-
2016
- 2016-05-31 IL IL245948A patent/IL245948B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US20160311797A1 (en) | 2016-10-27 |
AU2014369085B2 (en) | 2017-02-23 |
IL245948B (en) | 2019-08-29 |
MX2016007857A (es) | 2016-09-07 |
JP2016540796A (ja) | 2016-12-28 |
NZ720879A (en) | 2017-05-26 |
CN105873920A (zh) | 2016-08-17 |
WO2015092804A1 (en) | 2015-06-25 |
SG11201604849YA (en) | 2016-07-28 |
CA2932428A1 (en) | 2015-06-25 |
BR112016013974B1 (pt) | 2022-11-22 |
CA2932428C (en) | 2017-10-24 |
AP2016009253A0 (en) | 2016-06-30 |
EP3099675B1 (en) | 2018-02-14 |
US9951045B2 (en) | 2018-04-24 |
IL245948A0 (en) | 2016-08-02 |
BR112016013974A2 (pt) | 2017-08-08 |
JP6161823B2 (ja) | 2017-07-12 |
EP3099675A1 (en) | 2016-12-07 |
ES2668873T3 (es) | 2018-05-22 |
AU2014369085A1 (en) | 2016-06-30 |
CN105873920B (zh) | 2018-06-08 |
KR101824154B1 (ko) | 2018-03-14 |
DK3099675T3 (en) | 2018-05-22 |
EA201691252A1 (ru) | 2016-12-30 |
BR112016013974A8 (pt) | 2018-01-30 |
EA029951B1 (ru) | 2018-06-29 |
KR20160075832A (ko) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
EA201691302A1 (ru) | Новые гетероциклические соединения | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
EA201590748A1 (ru) | Противовирусные соединения против rsv | |
EA201490357A1 (ru) | Индазолы | |
TN2015000034A1 (en) | Derivatives of azaindazole or diazaindazole type for treating pain | |
EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
EA201700042A1 (ru) | Соединения имидазопиридазина | |
NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
TN2016000511A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
NZ720879A (en) | Indazole compounds as 5-ht4 receptor agonists | |
MX2014003455A (es) | Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide. | |
MX2014003584A (es) | Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides. | |
MX364929B (es) | Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |